St. Louis startup Prognosia, founded by WashU researchers, has been acquired by South Korea-based public company Lunit. The young firm, backed by BioSTL and BioGenerator Ventures, developed AI technology that analyzes mammograms to better predict breast cancer risk and recently earned FDA Breakthrough Device designation. The quick exit highlights BioSTL’s role in scouting talent and accelerating commercialization in the region. Prognosia’s founders will continue consulting with Lunit to advance the technology.
